Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.80)
# 88
Out of 5,182 analysts
46
Total ratings
68.63%
Success rate
40.71%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group | Maintains: Buy | $10 → $7 | $3.34 | +109.58% | 3 | Apr 17, 2026 | |
| ACOG Alpha Cognition | Initiates: Buy | $14 | $6.49 | +115.72% | 1 | Apr 17, 2026 | |
| NRXS NeurAxis | Maintains: Buy | $8 → $13 | $8.13 | +59.90% | 3 | Mar 20, 2026 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $30 → $35 | $23.45 | +49.25% | 8 | Mar 20, 2026 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $41.41 | +54.55% | 4 | Sep 23, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $6.83 | +104.98% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.58 | +183.84% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $6.12 | +79.74% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $6.32 | +74.05% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $5.48 | -45.26% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $17 | $11.59 | +46.68% | 3 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $16.57 | +135.37% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.04 | +98.02% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.84 | +93.73% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.06 | +47.78% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.90 | +12.36% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.53 | +126.93% | 2 | Jul 11, 2023 |
MiMedx Group
Apr 17, 2026
Maintains: Buy
Price Target: $10 → $7
Current: $3.34
Upside: +109.58%
Alpha Cognition
Apr 17, 2026
Initiates: Buy
Price Target: $14
Current: $6.49
Upside: +115.72%
NeurAxis
Mar 20, 2026
Maintains: Buy
Price Target: $8 → $13
Current: $8.13
Upside: +59.90%
Eton Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $23.45
Upside: +49.25%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $41.41
Upside: +54.55%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.83
Upside: +104.98%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.58
Upside: +183.84%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $6.12
Upside: +79.74%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.32
Upside: +74.05%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $5.48
Upside: -45.26%
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $11.59
Upside: +46.68%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $16.57
Upside: +135.37%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.04
Upside: +98.02%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.84
Upside: +93.73%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.06
Upside: +47.78%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.90
Upside: +12.36%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.53
Upside: +126.93%